Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo

BACKGROUND: Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to demonstrate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Ovarian Res
Autors principals: Zhou, Bo, Xia, Meng, Wang, Bin, Thapa, Niresh, Gan, Lijuan, Sun, Chaoyang, Guo, Ensong, Huang, Jia, Lu, Yulan, Cai, Hongbin
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6839134/
https://ncbi.nlm.nih.gov/pubmed/31703731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-019-0570-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars